MHC and MHC-like recognition |
I-Eb, k, s
|
Mouse |
Vγ1+/Vγ2 +
|
>240 µM (estimated) |
|
22,48,119 |
H-2k, b, f, q, s
|
Mouse |
Vγ2Vα11 |
N.D. |
|
30 |
HLA-A24 |
Human |
Vδ1+
|
N.D. |
Allo-HLA recognition |
31 |
HLA-B27-ci |
Human |
Vγ4Vδ1 |
N.D. |
Allo-HLA recognition |
32 |
HLA-A2 |
Human |
Vδ1+
|
N.D. |
Allo-HLA recognition |
33 |
HLA-A∗24:2 |
Human |
Vγ5Vδ1 |
N.D. |
Allo-HLA recognition but peptide loading required for increased stability of MHC |
23 |
HLA-A2/MART-1 |
Human |
Vδ1+
|
2.9–71 µM |
Response restricted to MHC-presented MART-1 peptide |
34 |
CD1-d |
Human/Mouse |
Vδ1+/Vδ3+
|
16–33 µM |
Affinity higher upon lipid-antigen presentation but binding also to non-presenting CD1-d |
12,24,35–37,39,40 |
CD1-c |
Human |
Vδ1+
|
23–125 µM |
Affinity higher upon lipid-antigen presentation but binding also to non-presenting CD1-c |
38 |
Qa-1b/Glu50Tyr50
|
Mouse |
N.D. |
N.D. |
Unclear, if antigen is presented or not |
41,42 |
MR-1 |
Human |
Vδ1+
|
2.7–30.6 µM |
No specificity for presented antigens |
43 |
EPCR |
Human |
Vγ4Vδ5 |
90 µM |
Generation of blocking antibody to identify antigen |
25 |
MICA |
Human |
Vδ1+
|
110–900 µM |
High-affinity NKG2D-ligand |
10,44–46 |
ULBP4 |
Human |
Vγ9Vδ2 |
N.D., but direct interaction shown by ELISA |
High-affinity NKG2D-ligand |
13 |
T10/T22 |
Mouse |
Diverse/clones G8 (Vγ4δ5) and KN6 (Vγ4δ10) |
0.1 µM |
Used for generation of γδ TCR-transgenic mice with defined specificity |
47–50 |
Ig-like recognition |
Annexin A2 |
Human |
Vγ8Vδ3 |
3 µM |
Generation of blocking antibody to identify antigen |
53 |
EphA2 |
Human |
Vγ9Vδ1 |
N.D. |
γδ TCR activation only if EphA2 is bound to ephrins on γδ T cell |
54 |
hMSH2 |
Human |
Vδ2+
|
N.D. |
High-affinity NKG2D-ligand |
55 |
Histidyl tRNA synthetase |
Human |
Vγ3Vδ2 |
N.D. |
Cell surface exposition not shown |
56,57 |
HSV-gI |
Mouse |
Vγ2Vδ8 |
N.D. |
Conformational epitope at N-terminus of HSV-gI |
58 |
SEA |
Human |
Vγ9+ (cytotoxic response), Vγ9− (cytotoxic response and proliferation) |
N.D. |
Superantigen from Staphylococcus aureus
|
59 |
OXYS |
Human |
Vγ9Vδ2 |
N.D. |
Superantigen from Bacillus Calmette-Guérin |
60 |
DX2 |
Human |
Vγ9Vδ2 |
N.D. |
Superantigen from Mycobacterium tuberculosis
|
61 |
Phycoerythrin (PE) |
Human, Mouse, Ruminants |
Human: Vγ1Vδ1 Mouse: Vγ1+/Vγ4+ (Spleen), Vγ7+ (intestine) |
2.69 µM (Mouse) |
No physiological antigen, protein from red algae |
62 |
Cy3 |
Mouse |
Vγ1+/Vγ4+
|
78.2 nM |
Hapten, no physiological antigen |
63 |
4-hydroxy-3-nitrophenyl acetyl (NP) |
Mouse |
Vγ1+
|
660 nM |
Hapten, no physiological antigen |
63 |
Insulin peptide B:9–23 |
Mouse |
Vγ1+ (without immunization), Vγ4+ (if immunized with peptide) |
N.D. |
Response idependent of APCs |
64,65 |
HSP-60 peptide |
Mouse |
Vγ1+
|
N.D. |
Peptides of mycobacterial and mammalian origin recognized |
66–68 |
Peptide from Listeriolysin O |
Human |
N.D. |
N.D. |
|
69 |
Peptide from Tetanus toxin |
Human |
Vγ9Vδ2 |
N.D. |
Presented by HLA-DRw53 |
70,71 |
Ig λ-chain |
Human |
N.D. |
N.D. |
Recognition if antigen is not on cell surface; presentation mechanism involved? |
72,73 |
Polyanionic molecules |
Mouse |
Vγ1Vδ6.3 |
N.D. |
Response independent of APCs |
74 |
B7 family-like proteins and phosphoantigen recognition |
BTN3A1 |
Human |
Vγ9Vδ2 |
N.D. |
Required for phosphoantigen response, binds phosphoantigen intracellularly, no direct interaction with γδ TCR shown to date |
90,91,94 |
BTN2A1 |
Human |
Vγ9Vδ2 |
40–50 µM |
Required for phosphoantigen response, Interaction with Vγ9-chain via HV4 and CDR2 |
103,104 |
Skint-1 |
Mouse |
Vγ5Vδ1 (DETC) |
N.D. |
Butyrophilin-like molecule required for homing of Vγ5Vδ1+ DETCs, direct interaction with γδ TCR not shown |
106–108 |
BTNL3 |
Human |
Vγ4+
|
SPR: 20.7 µM, ITC: 3.5 µM |
Heterodimer with BTNL8, interaction via HV4 and CDR2 of γ-chain, required probably for tissue homing and homeostasis |
113,114 |
Btnl6 |
Mouse |
Vγ7+
|
N.D. |
Heterodimer with Btnl6, mouse homologue of BTNL3, interaction via HV4 and CDR2 of γ-chain, required probably for tissue homing and homeostasis |
113 |